Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke

Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.

BACKGROUND Inflammatory and immune responses triggered by brain ischemia worsen clinical outcomes of stroke and contribute to hemorrhagic transformation, massive edema, and reperfusion injury associated with intravenous alteplase. We assessed whether a combination of the immune-modulator fingolimod and alteplase is safe and effective in attenuating reperfusion injury in patients with acute isch...

Combination of an Immune Modulator Fingolimod with Alteplase in Acute Ischemic Stroke: A Pilot Trial Running title: Zhu et al.; Combination of fingolimod with alteplase in stroke

Impact of an immune modulator fingolimod on acute ischemic stroke.

Peripheral lymphocytes entering brain ischemic regions orchestrate inflammatory responses, catalyze tissue death, and worsen clinical outcomes of acute ischemic stroke (AIS) in preclinical studies. However, it is not known whether modulating brain inflammation can impact the outcome of patients with AIS. In this open-label, evaluator-blinded, parallel-group clinical pilot trial, we recruited 22...

dysphagia in acute ischemic stroke

Introduction: Swallowing dysfunction complicates acute strokes in 25-32% of cases and directly affects patientschr('39') prognosis and recovery. Dysphagia complicates the course of acute strokes through its potential of the development of chest infection, nutritional problems, and dehydration.  Dysphagia is also an independent predictor of respiratory morbidity and mortality in acute stroke. In...

DRUG PROFILE Alteplase: thrombolysis for acute ischemic stroke

10.1586/14750708.2.5.709 © 2 Alteplase is the only licensed thrombolytic agent for the treatment of acute ischemic stroke. The body of evidence to date suggests that it reduces the number of stroke patients who are dead or dependent at follow up, despite the risk of intracranial hemorrhage. However, in Europe, the license has only been granted for people aged under 80 years who fulfil specific ...